Group 1 - The core viewpoint of the articles highlights the growth and innovation of the company "健康之路" (Health Road), which has established itself as a leading digital health service platform in China, leveraging AI technology to enhance healthcare services [1][2][4] - As of December 31, 2024, the platform boasts 889,000 registered doctors and 205 million registered personal users, indicating a vast user base that encourages more doctors to join, thereby improving service quality [1] - The company has developed various AI-driven platforms, such as the "AI援藏智慧医院平台" and "DIP智慧控费平台," which utilize AI and big data to enhance healthcare delivery and cost management [2] Group 2 - The company anticipates a profit of no less than 6 million yuan for the six months ending June 30, 2025, a significant turnaround from a loss of approximately 57.28 million yuan for the same period in 2024 [4] - The introduction of the "AI数字员工" (AI Digital Employee) system, which consists of a matrix of intelligent agents, is expected to improve service efficiency and reduce labor costs across various healthcare institutions [2] - Industry experts believe that the company is well-positioned to capitalize on the "AI + healthcare" market trend, potentially unlocking a second growth curve due to its extensive experience and resources accumulated over two decades in the digital healthcare sector [2]

健康之路(02587.HK) 8月8日晚间发布公告，根据董事会对本集团截至 2025 年 6 月 30 日止六个月的未 经审核综合管理账目的初步审阅及董事会目前可得资料，本集团预计将于截至 2025 年 6 月 30 日止六个 月录得不少于人民币 600 万元的溢利，而截至 2024 年 6 月 30 日止六个月则录得约人民币 5728 万元的 亏损， 二、价值医疗服务收入减少，主要由于本公司药品批发业务的若干销售代理协议于 2025 年届满，而本 公司正就新销售代理协议进行磋商，以及由于本公司主动调整服务结构及分类，健康医疗综合服务包的 收入减少； 三、数字营销服务收入减少，主要由于经济下滑，导致部分客户选择减少广告及营销开支。 有关本集团截至2025年6月30日止六个月之财务资料的详情，将于本公司截2025年 6 月 30 日止六个月之 中期业绩公告中披露，该公告预计于2025年8月下旬刊发。 据了解，健康之路股份有限公司是国经营数字健康医疗服务平台。 尽管出现上述增长，本集团预计截至 2025 年 6 月 30 日止六个月的收入与 2024 年同期相比将录得约 15% 至 18% 的减少，而截至 202 ...

Group 1 - The company expects to record a profit of no less than RMB 6 million for the six months ending June 30, 2025, compared to a loss of approximately RMB 57.28 million for the same period in 2024 [1] - The anticipated loss in 2024 is primarily due to changes in the redemption liability value from the termination of the priority rights of convertible redeemable preferred shares and expenses incurred during the listing preparation [1] - Despite the expected profit, the company forecasts a revenue decrease of approximately 15% to 18% for the six months ending June 30, 2025, compared to the same period in 2024 [1] Group 2 - The board believes the expected decrease in revenue and gross profit is mainly due to a reduction in content service revenue, as some clients have shifted to direct marketing strategies, reducing reliance on Real World Evidence (RWS) support services [2] - Increased competition in the generic drug industry has led to a shift of resources towards commercialization, resulting in budget cuts for RWS services from some clients [2] - The decline in value-added medical services revenue is attributed to the expiration of several sales agency agreements in 2025 and ongoing negotiations for new agreements, along with a proactive adjustment in service structure and classification [2] - A decrease in digital marketing service revenue is primarily due to the economic downturn, prompting some clients to reduce advertising and marketing expenditures [2]

Core Viewpoint - The company expects to achieve a profit of no less than RMB 6 million for the six months ending June 30, 2025, contrasting with a loss of approximately RMB 57.28 million for the same period in 2024, primarily due to changes in redeemable preference shares and listing expenses [1] Group 1: Financial Performance - The company anticipates a revenue decrease of approximately 15% to 18% for the six months ending June 30, 2025, compared to the same period in 2024 [1] - The gross profit for the six months ending June 30, 2025, is expected to decrease by about 8% to 12% compared to a gross profit of approximately RMB 184 million for the six months ending June 30, 2024 [1] Group 2: Revenue Decline Factors - The anticipated revenue decline is mainly due to a reduction in content service revenue, as some clients are shifting to direct marketing strategies, reducing their reliance on Real World Evidence (RWS) support services [2] - The decrease in value-added medical services revenue is attributed to the expiration of several sales agency agreements in 2025 and ongoing negotiations for new agreements, along with a proactive adjustment in service structure leading to reduced income from comprehensive healthcare service packages [2] - Digital marketing service revenue is also expected to decline due to economic downturns prompting clients to cut advertising and marketing expenditures [2]

Core Viewpoint - The company expects to achieve a profit of at least RMB 6 million for the six months ending June 30, 2025, contrasting with a loss of approximately RMB 57.28 million for the same period in 2024, primarily due to changes in redeemable preference shares and listing expenses [1] Group 1: Financial Performance - The company anticipates a revenue decrease of approximately 15% to 18% for the six months ending June 30, 2025, compared to the same period in 2024 [1] - The gross profit for the six months ending June 30, 2025, is expected to decrease by about 8% to 12% compared to a gross profit of approximately RMB 184 million for the six months ending June 30, 2024 [1] Group 2: Revenue Decline Factors - The anticipated revenue decline is mainly due to a reduction in content service revenue, as some clients are shifting to direct marketing strategies, reducing their reliance on Real World Evidence (RWS) support services [2] - The decrease in value-added medical service revenue is attributed to the expiration of several sales agency agreements in 2025 and ongoing negotiations for new agreements, along with a proactive adjustment in service structure [2] - Digital marketing service revenue is expected to decline due to economic downturns, leading some clients to cut advertising and marketing expenditures [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 HealthyWay Inc. 健康之路股份有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：2587） 內幕消息 本 公 告 由 健 康 之 路 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」），根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（「上市規則」）第13.09(2) (a)條及香港法例第571章證券及期貨條例第XIVA部 之 內 幕 消 息 條 文（定 義 見 上 市 規 則）而 作 出。 本 公 司 董 事 會（「董事會」）謹 此 知 會 本 公 司 股 東 及 潛 在 投 資 者，根 據 董 事 會對本集團截至2025年6月30日止六個月的未經審核綜合管理賬目的初 步 審 閱 及 董 事 會 目 前 可 得 資 料，本 ...

Group 1 - A-share market sees over 100 billion yuan in cash dividends as 30 companies announce mid-term dividend plans for 2025 [1] - The trend of multiple dividends per year is expected to become a standard practice among listed companies, with an anticipated increase in the number of companies implementing mid-term dividends in 2025 [1] - Tesla grants CEO Elon Musk 96 million shares of restricted stock, valued at approximately 29 billion dollars based on last week's closing price [3] Group 2 - In July 2025, nearly 2 million new investors entered the A-share market, marking a year-on-year increase of over 70% [3] - Cumulative new investors in the A-share market from January to July 2025 reached approximately 14.56 million, a significant increase of 36.9% compared to the same period in 2024 [3] Group 3 - The Ministry of Finance emphasizes the use of proactive fiscal policies to boost consumption and expand domestic demand [5] - The People's Bank of China advocates for moderately loose monetary policies to support technological innovation and stabilize foreign trade [5] - The China Securities Regulatory Commission aims to consolidate market stability and enhance regulatory effectiveness [5] Group 4 - Guizhou Moutai repurchased 345.17 million shares, spending a total of 5.301 billion yuan [26] - The company plans to reduce its registered capital through the repurchased shares [26] Group 5 - Guoquan Food plans to distribute a mid-term dividend of 190 million yuan, with a total shareholder return exceeding 499 million yuan for 2025, a 130.7% increase year-on-year [15] - Yutong Bus reports a cumulative sales increase of 2.63% in the first seven months of 2025 [15] Group 6 - ChipLink Integrated achieved a 21.38% increase in revenue for the first half of 2025, with AI revenue contributing 6% of total revenue [31] - The company reported a significant reduction in net loss, with a quarterly profit for the first time [31] Group 7 - China Heavy Industry is set to delist from A-shares as it merges with China Shipbuilding, with trading suspended from August 13, 2025 [22]

呈交日期: 2025年8月1日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 健康之路股份有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02587 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | 本月底法定/註冊股本 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 HealthyWay Inc. 健康之路股份有限公司 （於 開 曼 群 島 註 冊 成 立 之 有 限 公 司） （股 份 代 號：2587） 本公司截至二零二四年十二月三十一日止 年度的年報的補充公告 茲 提 述 健 康 之 路 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） 於二零二五年四月二十三日所刊發本公司截至二零二四年十二月三十一 日 止 年 度 的 年 報（「該年報」）。除 另 有 說 明 者 外，本 公 告 所 用 詞 彙 與 該 年 報 所 界 定 者 具 有 相 同 涵 義。 除 該 年 報 內 提 供 的 資 料 外，本 公 司 謹 此 提 供 以 下 補 充 資 料。 關聯方交易 本公司謹此就本集團的關 聯 方 交 易 澄 清，據 本 公 司 所 了 解，誠如該年報 第125頁 ...

7月16日恒生指数下跌0.29%，报收24517.76点，全天南向资金通过港股通渠道合计净买入16.03亿港 元。 证券时报·数据宝统计，7月16日港股通全天合计成交金额为1288.02亿港元，成交净买入16.03亿港元。 具体来看，沪市港股通成交金额819.58亿港元，成交净买入20.09亿港元；深市港股通成交金额468.44亿 港元，成交净卖出4.06亿港元。 | 代码 | 简称 | 类型 | 成交金额（万港元） | 成交净买入（万港元） | 日涨跌幅（%） | | --- | --- | --- | --- | --- | --- | | 09988 | 阿里巴巴-W | 港股通(沪) | 572834.28 | -34338.01 | 0.26 | | 01788 | 国泰君安国际 | 港股通(沪) | 567262.75 | 10080.56 | 4.93 | | 09992 | 泡泡玛特 | 港股通(沪) | 362346.76 | 31572.40 | -4.03 | | 09988 | 阿里巴巴-W | 港股通(深) | 307619.00 | 31374.96 | 0.26 | | 0070 ...